Last reviewed · How we verify
Oxycodone DETERx
Oxycodone DETERx is an extended-release formulation of oxycodone, a mu-opioid receptor agonist, designed with abuse-deterrent technology to reduce the potential for misuse.
Oxycodone DETERx is an extended-release formulation of oxycodone, a mu-opioid receptor agonist, designed with abuse-deterrent technology to reduce the potential for misuse. Used for Moderate to severe chronic pain requiring long-term opioid therapy.
At a glance
| Generic name | Oxycodone DETERx |
|---|---|
| Sponsor | Collegium Pharmaceutical, Inc. |
| Drug class | Opioid analgesic (abuse-deterrent formulation) |
| Target | Mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Oxycodone DETERx combines the opioid analgesic oxycodone with Collegium's proprietary DETERx technology, which is intended to make the drug resistant to common methods of abuse such as crushing, chewing, or dissolving. The formulation maintains the pharmacological action of oxycodone—binding to mu-opioid receptors in the central nervous system to produce analgesia—while the abuse-deterrent coating aims to reduce diversion and misuse potential.
Approved indications
- Moderate to severe chronic pain requiring long-term opioid therapy
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxycodone DETERx CI brief — competitive landscape report
- Oxycodone DETERx updates RSS · CI watch RSS
- Collegium Pharmaceutical, Inc. portfolio CI